ResMed Inc.
Rating
Updated: Aug 13, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operat...
Latest News
23 hours ago · marketbeat.com
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy DemandResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.
6 days ago · barrons.com
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.Setbacks for competitors have positioned ResMed to capture more market share.
7 days ago · seekingalpha.com
Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public call with Nvidia (NVDA) CEO Jensen Huang. ResMed (RMD) was upgraded to Outperform by RBC Capital Markets, with a price target raised to $262, citing strong Q4 results and expected high-single-digit EPS growth.
7 days ago · seekingalpha.com
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
7 days ago · zacks.com
Is This the Right Time to Retain Resmed Stock in Your Portfolio?RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
12 days ago · seekingalpha.com
ResMed: A Significant Upside Despite The Perceived RiskResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.
14 days ago · 247wallst.com
The IRS Lets You Send Your RMD Straight to Charity and Skip the Tax Entirely. These 3 ETFs Replace the Income You Gave AwayA Qualified Charitable Distribution can wipe your RMD off your tax return entirely, but it also kills the income you were counting on. Three ETFs can rebuild that cash flow, and they each do it a completely different way.
19 days ago · prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMDNEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
1 month ago · 247wallst.com
The IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching a ShareTurning 73 changes the math on your retirement account. The IRS no longer lets your traditional IRA compound in peace.
1 month ago · globenewswire.com
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron TaylorSAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RMD